This study tests a new drug, **tulisokibart (MK-7240)**, for people with moderate to severe **ulcerative colitis (UC)**, a disease causing swelling in the colon. The study has two parts. In Study 1, participants receive treatment for a longer time, with assessments at weeks 12 and 52. Study 2 is shorter, with a focus on the 12-week mark. The goal is to see if tulisokibart helps more people achieve **clinical remission**, meaning fewer or no symptoms, compared to a **placebo**, a pill with no medicine.

Key Points:

• The study lasts up to 52 weeks, depending on the part of the study you join.
• Participants must have had UC for at least 3 months and meet specific health criteria.
• Risks include possible side effects of the drug, similar to other strong medications.

Participants must not have other serious health issues or conditions that might confuse the results. If eligible, you can help research by joining but consider the time commitment and possible side effects. Discuss with your doctor if this opportunity suits you.